A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.
A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.
复制标题
用于治疗同时发生的可卡因和酒精依赖的可注射缓释纳曲酮的试点试验。
DOI：
10.1111/j.1521-0391.2014.12146.x
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
O'Brien,CharlesP
中科院分区：
文献类型：
--
作者：
Pettinati,HelenM;Kampman,KyleM;Lynch,KevinG;Dundon,WilliamD;Mahoney,ElizabethM;Wierzbicki,MichaelR;O'Brien,CharlesP
背景可卡因和酒精使用障碍的并发率很高，患有这两种问题的患者很难治疗。有合理的理由和一些经验数据来证明纳洛酮注射剂缓释制剂用于治疗并发的可卡因和酒精成瘾的先导试验是合理的。在为期8周的临床试验中，寻求治疗的受试者被随机分配接受两次每月一次的纳洛酮缓释注射或两次匹配的安慰剂注射，每周一次的医疗管理加认知行为治疗。结果注射纳洛酮和安慰剂组在8周的trial.ConclusionsInjectable延长释放纳洛酮，而一个理想的方法，以确保这些传统上难以治疗的患者的药物依从性，并没有导致任何可测量的减少可卡因或酒精的使用超过8周的治疗过程。(Am J Addict 2014;23：591-597）
BackgroundThere is a high co‐occurrence of cocaine and alcohol use disorders, and patients with both of these problems are difficult to treat. There is a reasonable rationale and some empirical data to justify a pilot trial of an injectable, extended‐release formulation of naltrexone for treating co‐occurring cocaine and alcohol addiction.MethodsEighty cocaine (n = 80) and alcohol dependent, treatment‐seeking subjects were randomly assigned to receive either two monthly extended‐release injections of naltrexone or two matching placebo injections in an 8‐week clinical trial, with weekly medical management plus cognitive behavioral therapy visits.ResultsNo differences in reduction in cocaine or alcohol use were observed between the injectable naltrexone and placebo groups during the 8‐week trial.ConclusionsInjectable extended‐release naltrexone, while an ideal method for ensuring medication adherence in these traditionally hard‐to‐treat patients, did not result in any measurable reduction in cocaine or alcohol use over the course of 8 weeks of treatment. (Am J Addict 2014;23:591–597)